Citadel Advisors
NGNE icon

Citadel Advisors’s Neurogene NGNE Stock Holding History

Citadel Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
408,982
+21,951
+6% +$604K ﹤0.01% 3192
2026
Q1 		$7.8M Buy
387,031
+22,803
+6% +$442K ﹤0.01% 3616
2025
Q4 		$7.5M Buy
+364,228
New +$9.07M ﹤0.01% 3659
2025
Q2 		– Sell
-16,416
Closed -$192K – 14199
2025
Q1 		$192K Buy
+16,416
New +$285K ﹤0.01% 10507
2023
Q4 		– Sell
-5,490
Closed -$86.7K – 14907
2023
Q3 		$86.7K Buy
5,490
+3,095
+129% +$45.7K ﹤0.01% 11069
2023
Q2 		$39.8K Buy
+2,395
New +$39.3K ﹤0.01% 12073
2022
Q3 		– Sell
-3,975
Closed -$82K – 13262
2022
Q2 		$82K Buy
3,975
+2,958
+291% +$72.2K ﹤0.01% 11578
2022
Q1 		$39K Buy
1,017
+153
+18% +$8.93K ﹤0.01% 12954
2021
Q4 		$83K Sell
864
-254
-23% -$30.9K ﹤0.01% 12904
2021
Q3 		$161K Buy
1,118
+590
+112% +$90.3K ﹤0.01% 12277
2021
Q2 		$97K Sell
528
-74
-12% -$16.4K ﹤0.01% 12942
2021
Q1 		$148K Sell
602
-1,791
-75% -$458K ﹤0.01% 12054
2020
Q4 		$675K Sell
2,393
-15,845
-87% -$3.87M ﹤0.01% 7567
2020
Q3 		$4.38M Buy
18,238
+15,601
+592% +$3.78M ﹤0.01% 3347
2020
Q2 		$875K Sell
2,637
-1,919
-42% -$500K ﹤0.01% 6068
2020
Q1 		$1.04M Buy
+4,556
New +$937K ﹤0.01% 5273
2019
Q2 		– Sell
-548
Closed -$30K – 9625
2019
Q1 		$30K Sell
548
-1,324
-71% -$66.9K ﹤0.01% 8995
2018
Q4 		$81K Sell
1,872
-9,894
-84% -$482K ﹤0.01% 8336
2018
Q3 		$689K Buy
11,766
+5,533
+89% +$326K ﹤0.01% 6185
2018
Q2 		$330K Buy
+6,233
New +$1.62M ﹤0.01% 7053
2018
Q1 		– Sell
-533
Closed -$147K – 8603
2017
Q4 		$125K Sell
533
-151
-22% -$35.4K ﹤0.01% 7348
2017
Q3 		$194K Buy
+684
New +$196K ﹤0.01% 6719

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Citadel Advisors's NGNE Position: Q2 2026 in Review

Citadel Advisors increased its Neurogene (NGNE) stake by 5.7% in Q2 2026, buying an estimated $604K and bringing the position to 408,982 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3192.

Citadel Advisors first reported a position in NGNE in Q3 2017 and has held it in 22 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Citadel Advisors held 408,982 shares of Neurogene worth $12.9M as of Q2 2026.
  • Citadel Advisors bought 21,951 Neurogene shares in Q2 2026, an estimated $604K.
  • Neurogene made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3192 holding.
  • Citadel Advisors first reported a position in Neurogene in Q3 2017 and has held it in 22 quarters since.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.